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1. Introduction
Pregnancy in patients with 
mechanical heart valves is 
associated with consider-
able morbidity, mortality and 
health cost utilisation. Management should be 
individualised in consultation with a multi-
disciplinary team including an obstetrician, a 
cardiologist and a haematologist to undertake 
laboratory monitoring, with appropriate consid-
eration for the risk/benefit ratio of each patient. 
We have designed practice guidelines to assist 
doctors and nurses caring for pregnant women 
with mechanical heart valves, with a view to 
achieving improved anticoagulation practice in 
this select group of high-risk patients.
2. Methodology
On behalf of the Southern African Society 
of Thrombosis and Haemostasis, a repre-
sentative guideline panel of professionals 
from the fields of haematology, cardiology 
and obstetrics reviewed the available English 
language literature on the anticoagulation 
of pregnant patients with mechanical heart 
valves on Pubmed. This included systematic 
reviews and randomised controlled trials as 
well as case series, observational studies and 
cohort studies. In addition, comprehensive 
evidence-based guidelines, namely the 9th 
edition of the American College of Chest 
Physicians (ACCP) and American Heart 
Association (AHA) guidelines,[1,2] were 
consulted and referenced where applicable. 
A draft document was produced and revised 
by consensus agreement. These resulting 
recommendations were adjudicated and 
co-authored by independent international 
experts to avoid local bias.
The recommendations have been graded 
as strong (grade 1) or weak (grade 2) 
according to the risks, adverse effects, health 
benefits and cost (Table 1).
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Table 1. Grading recommendation of the ACCP for antithrombotic therapy[1]
Grade Methodological quality of supporting evidence
1A Consistent evidence from RCTs without important limitations, or exceptionally 
strong evidence from observational studies
1B Evidence from RCTs with important limitations (inconsistent results, methodological 
flaws), or very strong evidence from observational studies
1C Evidence for at least one critical outcome from observational studies or case series, 
or from RCTs with serious flaws
2A Consistent evidence from RCTs without important limitations, or exceptionally 
strong evidence from observational studies
2B Evidence from RCTs with important limitations (inconsistent results, methodological 
flaws), or very strong evidence from observational studies
2C Evidence for at least one critical outcome from observational studies or case series, 
or from RCTs with serious flaws or indirect evidence
RCT = randomised controlled trial.
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3.  Anticoagulation of 
pregnant patients with 
mechanical valves
Anticoagulant therapy is essential because 
of the risk of valve thrombosis and systemic 
embolism (grade 1A).[3]
The ideal anticoagulant in pregnancy 
should be one that does not cross the 
placenta, to avoid teratogenicity and fetal 
haemorrhage, and one that can easily be 
reversed. Anticoagulants available for the 
management of pregnant patients with 
mechanical heart valves include:
• Vitamin K antagonists
• Unfractionated heparin (UFH)
• Low-molecular-weight heparin (LMWH).
These South African (SA) guidelines 
discuss the use of enoxaparin (Clexane; 
Sanofi Aventis), UFH and warfarin. (The 
recommendation to use enoxaparin 
only is based on the fact that adequate 
laboratory monitoring is available in SA 
for enoxaparin and not other LMWHs. The 
testing of LMWH is not interchangeable.) 
The choice of anticoagulant remains 
challenging, because both vitamin K anta-
gonists and heparins may be associated 
with maternal and fetal adverse events.[3-5] 
The choice of anticoagulation should be 
considered in conjunction with risk factors 
for thromboembolism (valve type, position 
and history of thromboembolism) and 
economic factors (availability and cost of the 
anticoagulants, access to laboratory testing 
and specialist care), as well as maternal 
preferences (Table 2).[1]
Pregnant patients with mechanical heart 
valves should be referred to a specialist 
antenatal clinic for management by a 
multidisciplinary team including an 
obstetrician and a cardiologist, with 
laboratory monitoring by a haematologist.
4. Anticoagulants
4.1 LMWH (enoxaparin)
LMWH does not cross the placenta, and is 
associated with improved fetal outcomes.
In pregnant patients, LMWH at fixed 
doses is less effective than warfarin 
therapy in preventing thromboembolic 
complications. LMWH therefore requires 
dose adjustment with laboratory monitoring 
(grade 1A).[1]
LMWH offers definite advantages over 
UFH because of its longer plasma half-life, 
dose-dependent clearance (resulting in a 
more predictable anticoagulant response), 
improved side-effect profile and less frequent 
monitoring requirements (grade 1B).[6]
Allergic skin reactions can occur with 
LMWH, but are uncommon.
4.1.1 LMWH dosage
The recommended dosage for enoxaparin is:
• Subcutaneous LMWH 12-hourly with 
dose adjustment to achieve a peak anti-Xa 
level ~1 U/mL (1.0 - 1.2 U/mL) 3 - 4 hours 
post injection.[1,2,7]
4.1.2 Monitoring of therapy
• LMWH activity is measured using an 
anti-Xa activity assay.
• Anti-Xa testing is performed by special-
ised National Health Laboratory Service 
central laboratories and private lab-
oratories in SA (Table 3).
• A 5 mL citrate tube is required for 
the assay. Avoid sampling blood from 
indwelling lines.
• Samples must reach the reference lab-
oratory (or local laboratory for shipping) 
within 1 hour.
• Samples must be drawn 3 - 4 hours after 
the last LMWH subcutaneous injection.
• Repeat testing is indicated until a 
therapeutic anti-Xa level is achieved (1.0 - 
1.2 U/mL).[2]
• A higher anti-Xa range than that proposed 
by international guidelines (0.7 - 1.2 U/
mL) is recommended owing to the high 
risk of valve thrombosis.[2,8]
• There is an increased dose requirement 
during pregnancy because of increased 
volume of distribution and renal clearance, 
and continued regular monitoring and 
dose adjustments (increase or decrease 
by 10 mg) according to anti-Xa levels are 
therefore recommended (Table 4).[7]
• Anti-Xa levels should be monitored 
weekly (as opposed to monthly) to 
reduce the likelihood of subtherapeutic 
anti-Xa levels and subsequent valve 
thrombosis.[8-10]
• The role of trough anti-Xa levels in 
adjusting the dose of LMWH is uncertain 
and pre-dose monitoring is not currently 
recommended.
Table 2. Factors affecting choice of 
anticoagulant
Risk factors for thromboembolism
Valve type
Valve position
History of thromboembolism
Economic factors
Availability of the anticoagulants
Cost of the anticoagulants
Access to laboratory testing
Access to specialist care
Maternal preferences
Fetal and maternal adverse outcomes
Table 3. Laboratories in SA that offer anti-Xa testing
Laboratory Contact number
National Health Laboratory Service central laboratories  
Charlotte Maxeke Johannesburg Academic Hospital, Gauteng (011) 489-8534
Red Cross War Memorial Children’s Hospital, Western Cape (021) 658-5203/4
Groote Schuur Hospital, Western Cape (021) 404-4151
 Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal (separated and 
referred on ice to Ampath NRL)
(031) 240-2677
 Private laboratories  
Ampath  
NRL, Gauteng or
Separated and referred on ice to Ampath NRL
(012) 678-0591
Lancet  
Milpark, Gauteng (011) 482-5406
Pencardia, Gauteng (012) 483-0100
Vermaak  
Unitas, Gauteng (012) 677-8341
Pathcare  
Cape Town, Western Cape (021) 596-3400
NRL = national referral laboratory.
LMWH (enoxaparin) with monitoring 
and dose adjustment is strongly 
recommended throughout pregnancy 
(grade 1A).
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4.1.3 Management of bleeding
• LMWH (plasma half-life 3 - 6 hours) should be discontinued, as 
well as any other agents that may contribute to bleeding.
• Measurement of anti-Xa levels is suggested.
• One intravenous (IV) dose of protamine sulphate can neutralise 
about 60 - 75% of the anti-Xa activity.[4]
• 1 mg protamine sulphate IV can be administered per 1 mg 
(equivalent to 100 anti-Xa units) enoxaparin, given in the last dose 
over 10 minutes.
• If the patient continues to bleed, a repeat dose of 0.5 mg protamine 
sulphate IV per 1 mg of enoxaparin, up to a maximum of three 
doses, may be administered in conjunction with replacement 
therapy.
4.2 UFH
UFH does not cross the placenta and is associated with improved 
fetal outcome.
UFH at fixed doses is less effective than warfarin in preventing 
maternal thromboembolic complications.[9,11] UFH therefore requires 
dose adjustment with frequent laboratory monitoring. Furthermore, 
the efficacy and dosage of adjusted-dose subcutaneous UFH has not 
been definitively established. The use of low-dose UFH is inade-
quate.[3] LMWH is recommended instead of UFH (grade 1B).[8]
Long-term UFH use is associated with an increased risk of 
heparin-induced thrombocytopenia (HIT), osteoporosis and allergic 
skin reactions.
4.2.1 UFH dosage
There is no consensus on the recommended dosage for UFH:
• Subcutaneous UFH in high doses 12-hourly with dose adjustment 6 
hours post injection to achieve an activated partial thromboplastin 
time (aPTT) ratio of 2 - 2.5 times the baseline value.[1,3,12]
4.2.2 Monitoring of therapy
• Anticoagulant activity is measured using an aPTT test.
• A 5 mL citrate tube is required for the assay. Avoid sampling blood 
from indwelling lines.
• Samples must reach the reference laboratory within 2 hours.
• Samples must be drawn 6 hours after the last UFH subcutaneous 
injection and repeated until a therapeutic aPTT is achieved (at 
least twice the baseline value).
• Once therapeutic levels are achieved, continued regular weekly 
monitoring with dose adjustments for changes with weight gain 
is recommended. UFH is more difficult to monitor owing to its 
unpredictable pharmacokinetics, and more frequent monitoring 
may be indicated.
• The patient’s platelet count should be monitored on initiation of 
UFH and 7 days later while on therapy to assess for HIT. If the 
patient has been exposed to UFH in the past 100 days, a repeat 
platelet count is indicated within 24 hours of starting UFH.
4.2.3 Management of bleeding
• UFH (plasma half-life 1 - 2 hours) should be discontinued, as well 
as any other agents that may contribute to bleeding.
• Measurement of aPTT levels may be indicated.
• If bleeding is life-threatening, immediate reversal of UFH activity 
can be achieved by administration of protamine sulphate.
• 1 mg of protamine sulphate IV should be administered per 1 mg 
(equivalent to 100 units of heparin) given in the last subcutaneous 
dose over 10 minutes.
• Rapid infusion can cause hypotension and convulsions.
• Following IV administration, neutralisation occurs within 5 
minutes. The maximum dose of protamine sulphate that can be 
administered is 50 mg.
4.3 Warfarin
Warfarin is the most effective anticoagulant for the prevention of 
valve thrombosis.[10] Warfarin is easy to administer and monitor.
Warfarin is safe during the first 6 weeks of gestation, but is 
associated with a teratogenic effect between 6 and 12 weeks. This 
results in a 4 - 10% risk of warfarin embryopathy (Table 5).[2-3,13,14] A 
dose-dependent (<5 mg/d) relationship for warfarin embryopathy 
has not been found in all cohorts.[15] Warfarin is therefore not 
recommended in the first trimester (grade 1A).[16-17]
In addition, there is an increased risk of fetal ocular and 
neurological abnormalities, a 30% risk of fetal loss, and an increased 
risk of fetal intracranial haemorrhage at any time during pregnancy, 
but particularly at the time of delivery.[3,18-21]
In pregnant women at higher risk of thromboembolism, such as 
those with older-generation valve types in the mitral position, e.g. 
Starr-Edwards and Bjork-Shiley, or a history of thromboembolism 
on heparin, warfarin can be considered throughout pregnancy with 
replacement by UFH or LMWH at 36 weeks (grade 2C).[7]
4.3.1 Warfarin dosage
The recommended dosage for warfarin is:
• 5 mg daily and the dose adjusted to achieve a target international 
normalised ratio (INR) of 3.0 (range 2.5 - 3.5).[1]
4.3.2 Monitoring of therapy
• Anticoagulant activity is monitored using an INR test.
• A 5 mL citrate tube is required for the assay. Avoid sampling blood 
from indwelling lines.
• INR monitoring is indicated every 1 - 4 weeks. The dose should be 
adjusted to achieve a target INR of 3.0 (range 2.5 - 3.5).
• Fluctuations of the INR outside the desired target range should be 
investigated.
Table 4. Interpretation of anti-Xa levels in patients on LMWH
Target anti-Xa levels
1.0 - 1.2 anti-Xa U/mL
Low anti-Xa level
Inadequate dosing
Delayed specimen draw
Dose of LMWH omitted
Weight gain
Gestation (volume of distribution of LMWH changes)
High anti-Xa level
Excessive dosing
Weight loss
Renal dysfunction
Reduced creatinine clearance (end of third trimester)
UFH is not recommended in pregnant patients with 
mechanical heart valves (grade 1B).
Warfarin in the first trimester is not recommended (grade 1A).
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4.3.3 Management of bleeding
• Women may go into preterm labour or 
develop complications requiring urgent 
delivery.
• Bleeding associated with warfarin therapy 
can be severe because of the drug’s long 
plasma half-life of 40 hours.
• If bleeding is significant, warfarin 
activity can be reversed immediately by 
administration of fresh-frozen plasma 
(15 - 20 mL/kg IV), prothrombin complex 
concentrates (50 U/kg) and/or vitamin K 
(1 - 2 mg) orally or intravenously.[22]
• Neonates born to mothers on warfarin will be 
over-anticoagulated, and caesarean section is 
the recommended mode of delivery.
• Assisted delivery with forceps and 
ventouse is contraindicated.[4]
• Maternal and neonatal INR monitoring is 
indicated daily.
4.4 Aspirin
The addition of low-dose aspirin in pregnant 
patients with mechanical heart valves is not 
routinely recommended (grade 2C).[1] 
5.  Management of 
pregnant patients with 
mechanical heart valves
The suggested regimen for anticoagulation 
in pregnant patients with mechanical heart 
valves is set out in Fig. 1.
5.1 Pre-pregnancy
• A multidisciplinary team needs to be 
involved in the management of pregnancy, 
including an obstetrician, a cardiologist 
and a haematologist, with easy access 
to an anaesthetist, a paediatrician and 
a geneticist as the time of delivery 
approaches.
• Discuss the choice of anticoagulant with 
the patient, detailing the risks and benefits 
for all anticoagulant options and other 
cardiac medications (Table 2).
• Continue warfarin until pregnancy is 
achieved (grade 2C).[1]
• Advise patients to present early to a 
specialist antenatal clinic when men-
struation is delayed.
5.2 Antenatal
The first visit to the antenatal clinic should 
include:
• A full history and examination, including 
cardiac, obstetric, haematological and 
anaesthetic assessment
• Baseline transthoracic echocardiography 
and 12-lead electrocardiography
• Antenatal bloods and INR (to exclude 
over-anticoagulation)
• A switch to subcutaneous LMWH, e.g. 
enoxaparin 1 mg/kg 12-hourly, is recom-
mended in the first trimester once the 
INR is ≤2.5 and if there are no signs or 
symptoms of bleeding (grade 1A).[1]
• Adjust the dose of LMWH (by 10 mg 
upwards or downwards) to achieve a 
peak anti-Xa level ~1 U/mL 3 - 4 hours 
post injection. Thereafter anti-Xa levels 
should be monitored, ideally on a weekly 
basis.[8]
Follow-up antenatal visits (in addition to 
routine obstetric management) include:
• A history of bleeding, valve thrombosis 
(chest pain, shortness of breath), peri-
pheral thromboembolic disease (focal 
neurological signs and symptoms)
• An examination of haematological (signs 
of bleeding, injection sites), cardiac 
(cardiac dysrythmias, congestive cardiac 
failure and auscultation to assess valve 
function), and neurological (signs of a 
cerebrovascular insult) systems
• Transthoracic echocardiography at the 
first antenatal visit and in the third tri-
mester, or if clinically indicated to exclude 
valve thrombosis
• Continued adjusted-dose subcutaneous 
LMWH until 38 weeks is strongly rec-
ommended (grade 1A) (Table 6).
Antenatal
• Present early to a specialist antenatal clinic when menstruation is delayed
• Switch to subcutaneous LMWH, e.g. enoxaparin (Clexane) 1 mg/kg 12-hourly with dose 
adjustment to achieve a peak anti-Xa level ~1 U/mL (1.0 - 1.2) 3 - 4 hours post injection
• Alternative anticoagulant options from the 13th week include substitution with warfarin from 
13 weeks until 36 weeks
Delivery
• Delivery at 38 weeks’ gestation
• Warfarin: Discontinue 2 weeks prior to delivery and switch to LMWH or IV UFH 
• LMWH: Admit and stop LMWH 24 hours prior to a planned delivery. Deliver by caesarean 
section or normal vaginal delivery when the anti-Xa is 0.2 - 0.5 U/mL
• UFH: Admit and stop UFH 36 hours prior to a planned delivery. Start IV UFH with aPTT 
monitoring 12-hourly to achieve an aPTT of 2 - 2.5 times the baseline aPTT. Discontinue 
when labour is established if a normal vaginal delivery is planned, or 4 - 6 hours prior to a 
caesarean section
Postpartum
• Neonate: Examination for warfarin embryopathy
• Maternal management: Restart heparin therapy 6 - 12 hours post delivery, or later if there is 
any evidence of bleeding from the surgical site
• UFH: Restart at the expected maintenance infusion with aPTT monitoring 12-hourly 
• LMWH: Restart at half the pre-delivery antepartum dose for the first 24 hours. Adjust dose to 
achieve an anti-Xa level of 0.8 - 1.0 U/mL
• Start warfarin at prior dose simultaneously with heparin
• Stop heparin once INR is therapeutic (2.5 - 3.5)
• Discharge to follow-up at an anticoagulation clinic (as per INR), obstetrics and cardiology at 
6 weeks post partum
Fig. 1. Suggested regimen for anticoagulation in pregnant patients with mechanical heart valves. 
Table 5. Adverse effects of warfarin in 
the fetus
Warfarin embryopathy (6 - 12 weeks)
Nasal hypoplasia
Stippled epiphyses
Saddle-nose deformity
Mental retardation
Optic atrophy
Frontal bossing
Hypertelorism
High-arched palate
Short neck
Short stature
Fetal effects (all trimesters and delivery)
Ocular abnormalities – blindness
 Neurological abnormalities – 
microcephaly, mental retardation, low 
intelligent quotients
Fetal loss
Bleeding
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• Alternative anticoagulant options from the 13th week include 
substitution with warfarin from 13 weeks until 36 weeks (grade 
1A) (Table 6).
• Close monitoring with dose adjustment is indicated. If the range is 
subtherapeutic and non-compliance is suspected, admission may 
be indicated.
5.3 Delivery
Delivery is planned at 38 weeks’ gestation. The mode of delivery is 
determined by the obstetrician.[23] In pregnant patients with HIV 
infection, specific guidelines should be consulted.
If warfarin is used, it should be discontinued 2 weeks prior to 
delivery and patients switched to LMWH or IV UFH. The fetal INR 
takes longer to normalise than the maternal INR, and delivery with the 
mother on warfarin poses a severe risk of haemorrhage to the fetus.
Suggested intrapartum anticoagulant protocols for delivery include:
5.3.1 LMWH
Suggested LMWH bridging regimen for peripartum anticoagulation:
• Admit and stop LMWH at least 24 hours prior to a planned 
delivery.
• Neuraxial anaesthesia should be avoided and epidural catheters 
should not be used (grade 1B).
• In order to reduce the risk of bleeding, anti-Xa levels should be 
used to guide the timing of delivery.[8]
• Perform serial anti-Xa testing 12 hours after the last dose of 
LMWH.
• Deliver by caesarean section or normal vaginal delivery when 
the anti-Xa level is 0.2 - 0.5 U/mL.
• Post induction of labour, if the anti-Xa level is <0.5 U/mL and 
the patient is not in the active phase of labour, delivery by 
caesarean section is recommended.
• Assess for major bleeding postpartum (resulting in a drop in the 
haemoglobin concentration by ≥2 g/dL, or bleeding requiring 
transfusion of at least two units of packed red blood cells).
5.3.2 UFH
Suggested UFH bridging regimen for peripartum anticoagulation:[4,24]
• Admit and stop anticoagulation at least 36 hours prior to a planned 
delivery.
• Start IV UFH 24 hours prior to delivery.
• Start IV UFH (5 000 - 10 000 U as an intravenous infusion in 
200 mL normal saline at 33 mL/h).
• aPTT monitoring is indicated 12-hourly to monitor UFH. Aim to 
achieve an aPTT of 2 - 2.5 times the baseline aPTT.
• Induction of labour: IV UFH therapy should be discontinued 
when labour is established. This should be individualised and 
determined by the risk of bleeding.
• Delivery by caesarean section: IV UFH therapy should be 
discontinued 4 - 6 hours prior to surgery.
• Assess for major bleeding postpartum (resulting in a drop in the 
haemoglobin concentration by ≥2 g/dL or as bleeding requiring 
transfusion of at least two units of packed red blood cells).
5.4 Post partum
5.4.1 Management of the neonate
The neonate requires examination by a paediatrician and/or geneticist 
for warfarin embryopathy.
5.4.2 Maternal management
Early reinstitution of anticoagulant therapy in these patients, in 
order to reduce the time off anticoagulation, results in a high risk of 
primary and secondary postpartum haemorrhage.[19]
Heparin therapy with LMWH or UFH should be restarted 6 - 12 
hours post delivery (see dosage below), or should be delayed if there 
is any evidence of bleeding from the surgical site.
Suggested postpartum regimens include:
5.4.2.1 UFH
• UFH should be restarted without a bolus, at no more than the 
expected maintenance infusion.[4] The PTT should be checked 
12 hours after restarting therapy to allow time for a stable 
anticoagulant response.
• IV UFH, with its short half-life, allows for more flexible anti-
coagulant control.
5.4.2.2 LMWH
• The anti-Xa level at delivery should guide the timing and dosing 
of LMWH.[8]
• After delivery, LMWH should be restarted at half the pre-delivery 
antepartum dose for the next 24 hours.
• The anti-Xa should be monitored 3 - 4 hours post therapeutic dose.
• Adjust the dose to achieve an anti-Xa level of 0.8 - 1.0 U/mL.
Start warfarin at previous dose simultaneously with LMWH. 
Warfarin therapy should be delayed post delivery in order to reduce 
the risk of major bleeding. Stop LMWH once the INR is therapeutic 
(2.5 - 3.5).
Discharge, for follow-up at an anticoagulation clinic (as per INR), 
and for cardiology and obstetrics and gynaecology follow-up at 6 
weeks post partum.
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Table 6. Recommended anticoagulant regimens[1] 
Adjusted-dose LMWH 12-hourly throughout pregnancy with dose adjustment to achieve a peak anti-Xa level ~1 U/mL 3 - 4 hours post injection (grade 1A)
LMWH (as above) until the 13th week with substitution by warfarin until close to delivery, when UFH or LMWH is resumed (grade 1A)
In pregnant women at higher risk of thromboembolism, such as those with older-generation valve types in the mitral position or a history of 
thromboembolism on heparin, warfarin can be considered throughout pregnancy with replacement by UFH or LMWH close to delivery (grade 2C)
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